布地奈德联合孟鲁司特钠对支原体肺炎患儿肺功能及MDC MCP-4的影响  

Effects of budesonide combined with montelukast sodium on pulmonary function,MDC and MCP-4 in children with mycoplasma pneumonia

作　　者：陈丽容 周逢洽[1] 余洽超[1] Chen Lirong;Zhou Fengqia;Yu Qiachao(The Kaiping Central Hospital,Kaiping,Guangdong 529300)

机构地区：[1]开平市中心医院,广东开平529300

出　　处：《基层医学论坛》2022年第22期29-31,58,共4页The Medical Forum

摘　　要：目的探讨布地奈德联合孟鲁司特钠对支原体肺炎患儿肺功能及MDC、MCP-4的影响。方法选取开平市中心医院收治的支原体肺炎患儿98例为对象,时间为2018年10月—2020年10月,随机数字表法分为对照组49例、研究组49例,2组均给予基础治疗,对照组在此基础上给予布地奈德治疗,研究组在对照组基础上联合孟鲁司特钠治疗。比较2组临床疗效、肺功能及血清MDC、MCP-4水平。结果研究组总有效率高于对照组(P<0.05)。与治疗前比较,治疗后2组患儿FVC、FEV_(1)、PEF均增加,研究组高于对照组;血清MDC、MCP-4水平均降低,研究组低于对照组(P<0.05或P<0.01)。治疗前2组患者炎症因子水平(白介素-2、白介素-4)对比无明显差异(P>0.05),研究组治疗后白介素-2水平较对照组低,白介素-4水平较对照组高,有统计学差异(P<0.05);对照组不良反应发生率为4.08%,研究组不良反应发生率为6.12%,组间对比无明显差异(P>0.05)。结论布地奈德联合孟鲁司特钠可更明显地降低支原体肺炎患儿细胞因子MDC、MCP-4水平、改善肺功能,疗效好。Objective To investigate the effects of budesonide combined with montelukast sodium on pulmonary function,MDC and MCP-4 in children with mycoplasma pneumonia.Methods 98 children with mycoplasma pneumonia treated in our hospital from October 2018 to October 2020 were randomly divided into 49 cases in the control group and 49 cases in the study group.Both groups were given basic treatment.The control group was treated with budesonide on this basis,and the study group was treated with montelukast sodium on the basis of the control group.The clinical efficacy,pulmonary function and serum MDC and MCP-4 levels were compared between the two groups.Results the total effective rate of the study group was higher than that of the control group(P<0.05).Compared with before treatment,FVC,FEV_(1) and PEF in the two groups increased after treatment,and the study group was greater than that in the control group;The levels of serum MDC and MCP-4 in the study group were lower than those in the control group(P<0.05 or P<0.01).There was no difference in the levels of inflammatory factors(interleukin-2 and interleukin-4)between the two groups before treatment(P>0.05).The level of interleukin-2 in the study group was lower than that in the control group after treatment,and the level of interleukin-4 was higher than that in the control group(P<0.05);The incidence of adverse reactions in the control group was 4.08%;The incidence of adverse reactions in the study group was 6.12%,and there was no difference between the groups(P>0.05).Conclusion Budesonide combined with montelukast sodium can significantly reduce the levels of cytokines MDC and MCP-4 in children with mycoplasma pneumonia and improve lung function.

关 键 词：支原体肺炎 布地奈德 孟鲁司特钠 肺功能 巨噬细胞衍生趋化因子 单核细胞趋化蛋白-4 

分 类 号：R452[医药卫生—治疗学]